Wednesday, December 4, 2019


ABEO Abeona Therapeutics Inc. gains 17% Dec 4, 2019

Abeona Therapeutics Inc., a biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company offers MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis. Its lead program is an adeno-associated virus (AAV)-based gene therapy for sanfilippo syndrome. The company develops ABO-101 for Mucopolysaccharidosis (MPS) III, a sanfilippo syndrome Type B; ABO-102 for MPS III, a sanfilippo syndrome Type A; ABO-201 for juvenile batten disease; ABO-301 for fanconi anemia; and clustered, regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 AAV for rare blood diseases. It also develops PTB-101 salt diafiltration process (SDF) Alpha, a alpha1-proteinase inhibitor for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe deficiency of alpha1-proteinase inhibitor; and PTB-102 SDF IVIG, an intravenous immunoglobulin for autoimmune, infectious, and idiopathic diseases. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive